Alexander Drilon

Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers

Nikolaus Schultz, Charles M. Rudin, Matthew D. Hellmann, 2018, Clinical Cancer Research.

Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children

Funda Meric-Bernstam, Ryma Benayed, Marc Ladanyi, 2018, The New England journal of medicine.

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14–mutant Non–small Cell Lung Cancer

Charles M. Rudin, Marissa Mattar, Elisa de Stanchina, 2018, Clinical Cancer Research.

Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions

Tatsuo Ito, Udayan Guha, Marc Ladanyi, 2012, Clinical Cancer Research.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Ross Camidge, Vamsidhar Velcheti, Thomas Filleron, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers.

David M. Hyman, David S. Hong, Alberto S. Pappo, 2017 .

Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas.

Lu Wang, Phil Stephens, Doron Lipson, 2013, Cancer discovery.

From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?

Chaya S Moskowitz, Dearbhail O'Driscoll, A. Drilon, 2015, Lung cancer.